JPH0411555B2 - - Google Patents

Info

Publication number: JPH0411555B2
Authority: JP; Japan
Prior art keywords: group; nucleotide; nucleoside; protected; groups
Prior art date: 1983-08-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP1023614A

Other languages

English (en)

Japanese (ja)

Other versions

JPH01301691A (ja

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-18

Filing date

1989-01-31

Publication date

1992-02-28

1989-01-31 Application filed filed Critical

1989-12-05 Publication of JPH01301691A publication Critical patent/JPH01301691A/ja

1992-02-28 Publication of JPH0411555B2 publication Critical patent/JPH0411555B2/ja

Status Granted legal-status Critical Current

Links

125000006239 protecting group Chemical group 0.000 claims abstract description 30
-1 nucleoside phosphate Chemical class 0.000 claims abstract description 29
125000003729 nucleotide group Chemical group 0.000 claims abstract description 28
239000002773 nucleotide Substances 0.000 claims abstract description 25
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
229910052794 bromium Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 4
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
125000000753 cycloalkyl group Chemical group 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
229910052717 sulfur Chemical group 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
125000001425 triazolyl group Chemical group 0.000 claims description 2
125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
239000002777 nucleoside Substances 0.000 abstract description 17
108091034117 Oligonucleotide Proteins 0.000 abstract description 16
238000006243 chemical reaction Methods 0.000 abstract description 15
238000000034 method Methods 0.000 abstract description 9
150000003833 nucleoside derivatives Chemical class 0.000 abstract description 9
150000003003 phosphines Chemical class 0.000 abstract description 9
229910019142 PO4 Inorganic materials 0.000 abstract description 8
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 8
150000001875 compounds Chemical class 0.000 abstract description 8
230000015572 biosynthetic process Effects 0.000 abstract description 7
239000010452 phosphate Substances 0.000 abstract description 7
230000003647 oxidation Effects 0.000 abstract description 5
238000007254 oxidation reaction Methods 0.000 abstract description 5
238000007068 beta-elimination reaction Methods 0.000 abstract description 4
238000003776 cleavage reaction Methods 0.000 abstract description 4
125000003835 nucleoside group Chemical group 0.000 abstract description 4
230000007017 scission Effects 0.000 abstract description 4
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract description 3
238000002360 preparation method Methods 0.000 abstract description 3
230000008030 elimination Effects 0.000 abstract 2
238000003379 elimination reaction Methods 0.000 abstract 2
235000021317 phosphate Nutrition 0.000 abstract 2
230000000903 blocking effect Effects 0.000 abstract 1
150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000002585 base Substances 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000012300 argon atmosphere Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
239000000460 chlorine Substances 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
238000003756 stirring Methods 0.000 description 5
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
238000005684 Liebig rearrangement reaction Methods 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
238000001502 gel electrophoresis Methods 0.000 description 4
239000011521 glass Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
239000012038 nucleophile Substances 0.000 description 3
125000004437 phosphorous atom Chemical group 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical group SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
ZSJQVOIPLQDHCE-UHFFFAOYSA-N 3-dichlorophosphanyloxypropanenitrile Chemical compound ClP(Cl)OCCC#N ZSJQVOIPLQDHCE-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
235000011114 ammonium hydroxide Nutrition 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
125000006575 electron-withdrawing group Chemical group 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000006260 foam Substances 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
150000003536 tetrazoles Chemical class 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
238000010626 work up procedure Methods 0.000 description 2
AFINAILKDBCXMX-PBHICJAKSA-N (2s,3r)-2-amino-3-hydroxy-n-(4-octylphenyl)butanamide Chemical compound CCCCCCCCC1=CC=C(NC(=O)[C@@H](N)[C@@H](C)O)C=C1 AFINAILKDBCXMX-PBHICJAKSA-N 0.000 description 1
SBKCKZYFAIFJPV-UHFFFAOYSA-N (6-amino-7h-purin-2-yl)-phenylmethanone Chemical group N=1C=2N=CNC=2C(N)=NC=1C(=O)C1=CC=CC=C1 SBKCKZYFAIFJPV-UHFFFAOYSA-N 0.000 description 1
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 1
RSCDYMIRBROPFY-UHFFFAOYSA-N 2-methyl-N-(2-oxo-1H-pyrimidin-6-yl)benzamide Chemical group C=1(C(=CC=CC=1)C(=O)NC1=NC(NC=C1)=O)C RSCDYMIRBROPFY-UHFFFAOYSA-N 0.000 description 1
CFIBTBBTJWHPQV-UHFFFAOYSA-N 2-methyl-n-(6-oxo-3,7-dihydropurin-2-yl)propanamide Chemical group N1C(NC(=O)C(C)C)=NC(=O)C2=C1N=CN2 CFIBTBBTJWHPQV-UHFFFAOYSA-N 0.000 description 1
SNJPVNBCEVUTJX-UHFFFAOYSA-N 3-(diaminophosphorylamino)propanenitrile Chemical compound NP(N)(=O)NCCC#N SNJPVNBCEVUTJX-UHFFFAOYSA-N 0.000 description 1
WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
KUEFXPHXHHANKS-UHFFFAOYSA-N 5-nitro-1h-1,2,4-triazole Chemical compound [O-][N+](=O)C1=NC=NN1 KUEFXPHXHHANKS-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
JGQCXFPVGXRVRX-UHFFFAOYSA-N C(#N)CCNP(=O)(N(C(C)C)C(C)C)N Chemical class C(#N)CCNP(=O)(N(C(C)C)C(C)C)N JGQCXFPVGXRVRX-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical group C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000004967 organic peroxy acids Chemical class 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
125000006245 phosphate protecting group Chemical group 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000007670 refining Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
ROWMQJJMCWDJDT-UHFFFAOYSA-N tribromomethane Chemical compound Br[C](Br)Br ROWMQJJMCWDJDT-UHFFFAOYSA-N 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
229940035893 uracil Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/26—Amides of acids of phosphorus containing P-halide groups
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)

JP1023614A 1983-08-18 1989-01-31 新規ヌクレオチド誘導体 Granted JPH01301691A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3329892.0		1983-08-18
DE19833329892 DE3329892A1 (de)	1983-08-18	1983-08-18	Verfahren zur herstellung von oligonucleotiden

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59503282A Division JPS60502102A (ja)	1983-08-18	1984-08-10	オリゴヌクレオチドの製造法

Publications (2)

Publication Number	Publication Date
JPH01301691A JPH01301691A (ja)	1989-12-05
JPH0411555B2 true JPH0411555B2 (2)	1992-02-28

Family

ID=6206891

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP59503282A Granted JPS60502102A (ja)	1983-08-18	1984-08-10	オリゴヌクレオチドの製造法
JP1023614A Granted JPH01301691A (ja)	1983-08-18	1989-01-31	新規ヌクレオチド誘導体

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
JP59503282A Granted JPS60502102A (ja)	1983-08-18	1984-08-10	オリゴヌクレオチドの製造法

Country Status (9)

Country	Link
US (1)	US4725677A (2)
EP (1)	EP0152459B1 (2)
JP (2)	JPS60502102A (2)
AT (1)	ATE38386T1 (2)
AU (1)	AU3313784A (2)
CA (1)	CA1234060A (2)
DE (2)	DE3329892A1 (2)
IT (1)	IT1198910B (2)
WO (1)	WO1985000816A1 (2)

Families Citing this family (403)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4973679A (en) *	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US5166330A (en) *	1983-09-06	1992-11-24	Hoechst Aktiengesellschaft	Process for the preparation of nucleoside alkyl-aralkyl- and aryl-phosphonites and -phosphonates
EP0222889B1 (en) *	1985-05-15	1993-10-27	Amoco Corporation	Cytidine analogs
EP0216357A3 (en) *	1985-09-25	1988-08-31	Nippon Zeon Co., Ltd.	Phosphoramidite compounds and process for production thereof
JPH0680071B2 (ja)	1985-10-07	1994-10-12	日本ゼオン株式会社	ホスホルアミダイト化合物及びその製造法
US4959463A (en) *	1985-10-15	1990-09-25	Genentech, Inc.	Intermediates
DE3788914T2 (de) *	1986-09-08	1994-08-25	Ajinomoto Kk	Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
WO1988003149A1 (fr) *	1986-10-30	1988-05-05	Daicel Chemical Industries, Ltd.	Procede de synthese d'oligonucleotides et composes servant a former des groupes protecteurs a poids moleculaire eleve
US6306647B1 (en)	1987-06-16	2001-10-23	Ajinomoto Co., Inc.	Process for producing and purifying 2′,3′-dideoxynucleosides, and process for producing 2′,3′-dideoxy-2′,3′-didehydronucleosides
US4835104A (en) *	1987-06-16	1989-05-30	Ajinomoto Co., Inc., Patent & Licensing Department	Process for producing and purifying 2',3'-dideoxynucleosides, and process for producing 2',3'-dideoxy-2',3'-didehydronucleosides
US5585481A (en) *	1987-09-21	1996-12-17	Gen-Probe Incorporated	Linking reagents for nucleotide probes
US6031091A (en) *	1987-09-21	2000-02-29	Gen-Probe Incorporated	Non-nucleotide linking reagents for nucleotide probes
WO1989009221A1 (en) *	1988-03-25	1989-10-05	University Of Virginia Alumni Patents Foundation	Oligonucleotide n-alkylphosphoramidates
WO1989009780A1 (en) *	1988-04-15	1989-10-19	Chemical Industry Institute Of Toxicology	Site-specific tritium-labeled oligodeoxynucleotides
US5602244A (en) *	1988-05-26	1997-02-11	Competitive Technologies, Inc.	Polynucleotide phosphorodithioate compounds
US5750666A (en) *	1988-05-26	1998-05-12	Competitve Technologies, Inc.	Polynucleotide phosphorodithioate compounds
JP3028814B2 (ja) *	1988-06-28	2000-04-04	ベイラーカレッジオブメディシン	生体高分子の分割合成のための多孔質ウエハー
JPH0291088A (ja) *	1988-09-29	1990-03-30	Central Glass Co Ltd	ホスファイトおよびヌクレオシド‐３’‐ホスファイト誘導体およびこれを用いるオリゴヌクレオチドの合成法
CA2000805C (en) *	1988-10-17	1994-01-18	Kiyoshi Sudani	Carbon/metal composite
US5047524A (en) *	1988-12-21	1991-09-10	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5262530A (en) *	1988-12-21	1993-11-16	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
DE3916871A1 (de) *	1989-05-24	1990-11-29	Boehringer Mannheim Gmbh	Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
US7049102B1 (en)	1989-09-22	2006-05-23	Board Of Trustees Of Leland Stanford University	Multi-gene expression profile
US5545522A (en)	1989-09-22	1996-08-13	Van Gelder; Russell N.	Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5914396A (en) *	1990-01-11	1999-06-22	Isis Pharmaceuticals, Inc.	2'-O-modified nucleosides and phosphoramidites
US5151510A (en) *	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
ATE171947T1 (de) *	1990-10-26	1998-10-15	Genta Inc	Verbessertes verfahren zur synthese von oligomeren
US6335434B1 (en)	1998-06-16	2002-01-01	Isis Pharmaceuticals, Inc.,	Nucleosidic and non-nucleosidic folate conjugates
US5594121A (en) *	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
AU3222793A (en) *	1991-11-26	1993-06-28	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) *	1991-11-26	2000-06-11	Isis Pharmaceuticals Inc	Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
ZA929351B (en) *	1991-12-11	1993-06-04	Igen Inc	Electrochemiluminescent label for DNA assays.
AU3250093A (en)	1991-12-12	1993-07-19	Gilead Sciences, Inc.	Nuclease stable and binding competent oligomers and methods for their use
US5795714A (en) *	1992-11-06	1998-08-18	Trustees Of Boston University	Method for replicating an array of nucleic acid probes
US6436635B1 (en) *	1992-11-06	2002-08-20	Boston University	Solid phase sequencing of double-stranded nucleic acids
US6194144B1 (en)	1993-01-07	2001-02-27	Sequenom, Inc.	DNA sequencing by mass spectrometry
CA2153387A1 (en)	1993-01-07	1994-07-21	Hubert Koester	Dna sequencing by mass spectrometry
US5605798A (en)	1993-01-07	1997-02-25	Sequenom, Inc.	DNA diagnostic based on mass spectrometry
US5955591A (en) *	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
US5428149A (en) *	1993-06-14	1995-06-27	Washington State University Research Foundation	Method for palladium catalyzed carbon-carbon coulping and products
HUT74597A (en)	1993-06-23	1997-01-28	Genesys Pharma Inc	Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
US6294664B1 (en)	1993-07-29	2001-09-25	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides
US5614621A (en) *	1993-07-29	1997-03-25	Isis Pharmaceuticals, Inc.	Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
US5571902A (en) *	1993-07-29	1996-11-05	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides
US6001982A (en)	1993-07-29	1999-12-14	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides
AU679566B2 (en)	1993-09-03	1997-07-03	Isis Pharmaceuticals, Inc.	Amine-derivatized nucleosides and oligonucleosides
US6639061B1 (en)	1999-07-07	2003-10-28	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate oligomers and related compounds
US5510476A (en) *	1994-07-07	1996-04-23	Isis Pharmaceuticals, Inc.	Carbocation scavenging during oligonucleotide synthesis
US6558633B1 (en)	1994-09-21	2003-05-06	Isis Pharmaceuticals, Inc.	Chemical reaction apparatus and methods
USRE43097E1 (en)	1994-10-13	2012-01-10	Illumina, Inc.	Massively parallel signature sequencing by ligation of encoded adaptors
US5604097A (en)	1994-10-13	1997-02-18	Spectragen, Inc.	Methods for sorting polynucleotides using oligonucleotide tags
US6428955B1 (en)	1995-03-17	2002-08-06	Sequenom, Inc.	DNA diagnostics based on mass spectrometry
US7803529B1 (en)	1995-04-11	2010-09-28	Sequenom, Inc.	Solid phase sequencing of biopolymers
US20060063193A1 (en) *	1995-04-11	2006-03-23	Dong-Jing Fu	Solid phase sequencing of double-stranded nucleic acids
US5750341A (en)	1995-04-17	1998-05-12	Lynx Therapeutics, Inc.	DNA sequencing by parallel oligonucleotide extensions
US5830655A (en)	1995-05-22	1998-11-03	Sri International	Oligonucleotide sizing using cleavable primers
US6111095A (en) *	1995-06-07	2000-08-29	Merck & Co., Inc.	Capped synthetic RNA, analogs, and aptamers
CA2222581C (en)	1995-06-07	2004-05-11	Lynx Therapeutics, Inc.	Oligonucleotide tags for sorting and identification
US6146854A (en) *	1995-08-31	2000-11-14	Sequenom, Inc.	Filtration processes, kits and devices for isolating plasmids
EP0863910A1 (en)	1995-10-19	1998-09-16	NeXstar Pharmaceuticals, Inc.	Method for solution phase synthesis of oligonucleotides
US5734041A (en)	1995-10-20	1998-03-31	Mcgill University	Preparation of chiral phosphorothioate oligomers
US6160109A (en) *	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US6476216B1 (en) *	1995-10-20	2002-11-05	Mcgill University	Preparation of phosphorothioate oligomers
US5705621A (en) *	1995-11-17	1998-01-06	Isis Pharmaceuticals, Inc.	Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
US20030119724A1 (en) *	1995-11-22	2003-06-26	Ts`O Paul O.P.	Ligands to enhance cellular uptake of biomolecules
US5808035A (en) *	1995-12-08	1998-09-15	Usher; David A.	Protected nucleoside and method for its synthesis
EP0932698A1 (en) *	1996-03-26	1999-08-04	Lynx Therapeutics, Inc.	Oligonucleotide treatments and compositions for human melanoma
US5959100A (en) *	1996-03-27	1999-09-28	Nexstar Pharmaceuticals, Inc.	Pyrimidine nucleosides as therapeutic and diagnostic agents
US20040203024A1 (en) *	1996-06-06	2004-10-14	Baker Brenda F.	Modified oligonucleotides for use in RNA interference
US7812149B2 (en) *	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040171031A1 (en) *	1996-06-06	2004-09-02	Baker Brenda F.	Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US20050119470A1 (en) *	1996-06-06	2005-06-02	Muthiah Manoharan	Conjugated oligomeric compounds and their use in gene modulation
US20070275921A1 (en) *	1996-06-06	2007-11-29	Isis Pharmaceuticals, Inc.	Oligomeric Compounds That Facilitate Risc Loading
US20050053976A1 (en) *	1996-06-06	2005-03-10	Baker Brenda F.	Chimeric oligomeric compounds and their use in gene modulation
US20040147022A1 (en) *	1996-06-06	2004-07-29	Baker Brenda F.	2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US5777324A (en)	1996-09-19	1998-07-07	Sequenom, Inc.	Method and apparatus for maldi analysis
US6024925A (en)	1997-01-23	2000-02-15	Sequenom, Inc.	Systems and methods for preparing low volume analyte array elements
DE69738206T2 (de) *	1996-11-06	2008-07-17	Sequenom, Inc., San Diego	DNA-Diagnostik mittels Massenspektrometrie
ES2215241T3 (es)	1996-11-06	2004-10-01	Sequenom, Inc.	Procedimiento de espectrometria de masa.
US6133436A (en)	1996-11-06	2000-10-17	Sequenom, Inc.	Beads bound to a solid support and to nucleic acids
US7285422B1 (en) *	1997-01-23	2007-10-23	Sequenom, Inc.	Systems and methods for preparing and analyzing low volume analyte array elements
US6140053A (en) *	1996-11-06	2000-10-31	Sequenom, Inc.	DNA sequencing by mass spectrometry via exonuclease degradation
US6060240A (en) *	1996-12-13	2000-05-09	Arcaris, Inc.	Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6172217B1 (en)	1996-12-27	2001-01-09	Isis Pharmaceuticals Inc.	Method of synthesizing phosphorothioate oligonucleotides
US5902881A (en)	1997-03-03	1999-05-11	Isis Pharmaceuticals, Inc.	Reagent useful for synthesizing sulfurized oligonucleotide analogs
US5760209A (en) *	1997-03-03	1998-06-02	Isis Pharmaceuticals, Inc.	Protecting group for synthesizing oligonucleotide analogs
US6207370B1 (en)	1997-09-02	2001-03-27	Sequenom, Inc.	Diagnostics based on mass spectrometric detection of translated target polypeptides
US6268131B1 (en)	1997-12-15	2001-07-31	Sequenom, Inc.	Mass spectrometric methods for sequencing nucleic acids
US7427678B2 (en) *	1998-01-08	2008-09-23	Sigma-Aldrich Co.	Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
US6326479B1 (en)	1998-01-27	2001-12-04	Boston Probes, Inc.	Synthetic polymers and methods, kits or compositions for modulating the solubility of same
US6020475A (en) *	1998-02-10	2000-02-01	Isis Pharmeuticals, Inc.	Process for the synthesis of oligomeric compounds
US7273933B1 (en)	1998-02-26	2007-09-25	Isis Pharmaceuticals, Inc.	Methods for synthesis of oligonucleotides
US6531590B1 (en)	1998-04-24	2003-03-11	Isis Pharmaceuticals, Inc.	Processes for the synthesis of oligonucleotide compounds
US7875440B2 (en)	1998-05-01	2011-01-25	Arizona Board Of Regents	Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6780591B2 (en) *	1998-05-01	2004-08-24	Arizona Board Of Regents	Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6723564B2 (en)	1998-05-07	2004-04-20	Sequenom, Inc.	IR MALDI mass spectrometry of nucleic acids using liquid matrices
US6274725B1 (en)	1998-06-02	2001-08-14	Isis Pharmaceuticals, Inc.	Activators for oligonucleotide synthesis
US6919437B1 (en)	1998-06-11	2005-07-19	Isis Pharmaceuticals, Inc.	Synthetic methods and intermediates for triester oligonucleotides
US6335439B1 (en)	1998-06-11	2002-01-01	Isis Pharmaceuticals, Inc.	Method of preparing phosphoramidites
US6326478B1 (en)	1998-07-08	2001-12-04	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6124484A (en)	1998-07-17	2000-09-26	Isis Pharmaceuticals, Inc.	Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis
US6673912B1 (en)	1998-08-07	2004-01-06	Isis Pharmaceuticals, Inc.	2′-O-aminoethyloxyethyl-modified oligonucleotides
US6043352A (en)	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US20040009938A1 (en) *	1998-08-07	2004-01-15	Muthiah Manoharan	Methods of enhancing renal uptake of oligonucleotides
US6335437B1 (en)	1998-09-07	2002-01-01	Isis Pharmaceuticals, Inc.	Methods for the preparation of conjugated oligomers
US6069243A (en) *	1998-10-06	2000-05-30	Isis Pharmaceuticals, Inc.	Process for oligonucleotide synthesis
US6153411A (en) *	1998-10-30	2000-11-28	American Water Works Company, Inc.	Methods and kits for detection of Cryptosporidium parvum using immunomagnetic separation and amplification
US6169177B1 (en)	1998-11-06	2001-01-02	Isis Pharmaceuticals, Inc.	Processes for the synthesis of oligomeric compounds
US6264891B1 (en) *	1998-12-22	2001-07-24	Eos Biotechnology, Inc.	Apparatus and method for concurrent chemical synthesis
US6380378B1 (en)	1998-12-24	2002-04-30	Toagosei Company, Ltd.	Nucleotide compound, nucleotide block oligonucleotide, and method for producing them
US6465628B1 (en) *	1999-02-04	2002-10-15	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
US6207819B1 (en)	1999-02-12	2001-03-27	Isis Pharmaceuticals, Inc.	Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6225061B1 (en)	1999-03-10	2001-05-01	Sequenom, Inc.	Systems and methods for performing reactions in an unsealed environment
US6121437A (en) *	1999-03-16	2000-09-19	Isis Pharmaceuticals, Inc.	Phosphate and thiophosphate protecting groups
US20040082774A1 (en) *	1999-03-16	2004-04-29	Guzaev Andrei P.	Novel phosphate and thiophosphate protecting groups
US6399765B1 (en) *	1999-03-17	2002-06-04	Isis Pharmaceuticals, Inc.	Methods for removing dimethoxytrityl groups from oligonucleotides
AU2998800A (en)	1999-03-24	2000-10-09	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	N-acylphosphoramidites and their use in oligonucleotide synthesis
US6610842B1 (en)	1999-05-06	2003-08-26	Isis Pharmaceuticals, Inc.	Processes for the synthesis of oligomers using phosphoramidite compositions
US6221635B1 (en)	1999-05-06	2001-04-24	The Wistar Institute	Methods for solid-phase amplification of DNA template (SPADT) using multiarrays
US20070059752A1 (en) *	1999-06-09	2007-03-15	Biosearch Technologies, Inc.	Fluorescence energy transfer probes with stabilized conformations
US7501245B2 (en) *	1999-06-28	2009-03-10	Helicos Biosciences Corp.	Methods and apparatuses for analyzing polynucleotide sequences
US6818395B1 (en) *	1999-06-28	2004-11-16	California Institute Of Technology	Methods and apparatus for analyzing polynucleotide sequences
US6414135B1 (en)	1999-07-07	2002-07-02	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate monomers and related compounds
US6593466B1 (en)	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6114518A (en) *	1999-09-30	2000-09-05	Becton, Dickinson And Company	Synthesis and use of labelled phosphoramidite compositions
US7019129B1 (en)	2000-05-09	2006-03-28	Biosearch Technologies, Inc.	Dark quenchers for donor-acceptor energy transfer
US6936702B2 (en) *	2000-06-07	2005-08-30	Li-Cor, Inc.	Charge-switch nucleotides
JP2004516810A (ja)	2000-06-07	2004-06-10	リ−コールインコーポレーティッド	電荷スイッチヌクレオチド
US7135565B2 (en) *	2000-07-28	2006-11-14	Agilent Technologies, Inc.	Synthesis of polynucleotides using combined oxidation/deprotection chemistry
ATE432994T1 (de)	2000-09-26	2009-06-15	Boston Probes Inc	Sonden, sondensätzen,verfahren und kits zur nachweis, identifizierung und/oder die zählung von bakterien
US6693187B1 (en) *	2000-10-17	2004-02-17	Lievre Cornu Llc	Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20020142483A1 (en)	2000-10-30	2002-10-03	Sequenom, Inc.	Method and apparatus for delivery of submicroliter volumes onto a substrate
US6906182B2 (en)	2000-12-01	2005-06-14	Cell Works Therapeutics, Inc.	Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
US6794141B2 (en)	2000-12-22	2004-09-21	Arcturus Bioscience, Inc.	Nucleic acid amplification
EP1368497A4 (en) *	2001-03-12	2007-08-15	California Inst Of Techn	METHODS AND APPARATUS FOR ANALYZING ASYNCHRONOUS BASE EXTENSION POLYNUCLEOTIDE SEQUENCES
US6825338B2 (en)	2001-03-30	2004-11-30	Isis Pharmaceuticals, Inc.	Labeled oligonucleotides, methods for making same, and compounds useful therefor
PL373962A1 (en) *	2001-05-21	2005-09-19	Aclara Biosciences, Inc.	Methods and compositions for analyzing proteins
US7118907B2 (en) *	2001-06-06	2006-10-10	Li-Cor, Inc.	Single molecule detection systems and methods
AU2002322351A1 (en) *	2001-06-28	2003-03-03	Ia, Inc.	Fiber-optic sensor array
JP3935487B2 (ja) *	2001-07-16	2007-06-20	フーベルト・ケスター	捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法
US6822088B2 (en)	2001-07-17	2004-11-23	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides on solid support
WO2003048179A2 (en) *	2001-12-03	2003-06-12	The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services	Thermolabile hydroxyl protecting groups and methods of use
US7255874B1 (en)	2001-12-21	2007-08-14	Closure Medical Corporation	Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
GB0200526D0 (en) *	2002-01-11	2002-02-27	Science And Technology The	Methods
AU2003210629A1 (en) *	2002-01-23	2003-09-02	Proligo, Llc	Methods for the integrated synthesis and purification of oligonucleotides
CN100379709C (zh) *	2002-02-22	2008-04-09	霍尼韦尔国际公司	制备亚磷酸酯化(phosphitylated)化合物的方法
EP1502102B1 (en) *	2002-03-11	2009-01-14	caprotec bioanalytics GmbH	Compounds and methods for analyzing the proteome
EP1485503A4 (en) *	2002-03-15	2005-12-28	Arcturus Bioscience Inc	IMPROVED NUCLEIC ACID AMPLIFICATION
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
DE60328674D1 (de)	2002-04-17	2009-09-17	Bioren Inc	Universelle banken für immunoglobuline
AU2003249681A1 (en) *	2002-05-31	2003-12-19	Diversa Corporation	Multiplexed systems for nucleic acid sequencing
US6967247B2 (en)	2002-07-24	2005-11-22	Isis Pharmaceuticals, Inc.	Deprotection of phosphorus in oligonucleotide synthesis
US20040137469A1 (en) *	2002-09-08	2004-07-15	Casale Ralph A	Methods, compositions and libraries pertaining PNA dimer and PNA oligomer synthesis
US8604183B2 (en) *	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150605B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP1585755B1 (en) *	2002-12-31	2015-08-05	Sigma-Aldrich Co. LLC	Methods and compositions for the tandem synthesis of two or more oligonuleotides on the same solid support
EP2259068B1 (en) *	2003-01-16	2013-08-14	caprotec bioanalytics GmbH	Capture compounds and methods for analyzing the proteome
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
US7745116B2 (en) *	2003-04-08	2010-06-29	Pacific Biosciences Of California, Inc.	Composition and method for nucleic acid sequencing
EP1660512A4 (en) *	2003-06-02	2009-12-23	Isis Pharmaceuticals Inc	SYNTHESIS OF OLIGONUCLEOTIDES USING ALTERNATIVE SOLVENTS
US20050170367A1 (en) *	2003-06-10	2005-08-04	Quake Stephen R.	Fluorescently labeled nucleoside triphosphates and analogs thereof for sequencing nucleic acids
US20060241072A1 (en) *	2003-06-20	2006-10-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds for use in gene modulation
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
WO2005027962A1 (en)	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides and oligomeric compounds
US7125945B2 (en) *	2003-09-19	2006-10-24	Varian, Inc.	Functionalized polymer for oligonucleotide purification
US7169560B2 (en)	2003-11-12	2007-01-30	Helicos Biosciences Corporation	Short cycle methods for sequencing polynucleotides
ES2403937T3 (es)	2003-11-13	2013-05-22	Isis Pharmaceuticals, Inc.	Derivados de 5,6-dihidroxi-isoindol como conectores para la síntesis de oligómeros en fase sólida
US20060172408A1 (en) *	2003-12-01	2006-08-03	Quake Steven R	Device for immobilizing chemical and biochemical species and methods of using same
US7691316B2 (en) *	2004-02-12	2010-04-06	Chemistry & Technology For Genes, Inc.	Devices and methods for the synthesis of nucleic acids
WO2005080605A2 (en)	2004-02-19	2005-09-01	Helicos Biosciences Corporation	Methods and kits for analyzing polynucleotide sequences
US20060046258A1 (en) *	2004-02-27	2006-03-02	Lapidus Stanley N	Applications of single molecule sequencing
JP4814084B2 (ja) *	2004-03-05	2011-11-09	株式会社キラルジェン	ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005085272A1 (ja) *	2004-03-05	2005-09-15	Takeshi Wada	ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
US8569474B2 (en) *	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US20050239085A1 (en) *	2004-04-23	2005-10-27	Buzby Philip R	Methods for nucleic acid sequence determination
US20050260609A1 (en) *	2004-05-24	2005-11-24	Lapidus Stanley N	Methods and devices for sequencing nucleic acids
US7476734B2 (en) *	2005-12-06	2009-01-13	Helicos Biosciences Corporation	Nucleotide analogs
DE602005027700D1 (de) *	2004-05-25	2011-06-09	Helicos Biosciences Corp	Verfahren zur nukleinsäureimmobilisierung
US20070117104A1 (en) *	2005-11-22	2007-05-24	Buzby Philip R	Nucleotide analogs
US20070117103A1 (en) *	2005-11-22	2007-05-24	Buzby Philip R	Nucleotide analogs
US20090048192A1 (en) *	2004-06-03	2009-02-19	Isis Pharmaceuticals, Inc.	Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
AU2005252663B2 (en) *	2004-06-03	2011-07-07	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
US8394947B2 (en) *	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US20060024678A1 (en) *	2004-07-28	2006-02-02	Helicos Biosciences Corporation	Use of single-stranded nucleic acid binding proteins in sequencing
WO2006023880A2 (en) *	2004-08-23	2006-03-02	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) *	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US7772439B2 (en) *	2004-10-25	2010-08-10	Operon Biotechnologies, Inc.	Amino or thiol linker building block for the synthesis of amino- or thiol-functionalized nucleic acids and methods of making and use thereof
ATE505540T1 (de)	2004-11-16	2011-04-15	Qiagen Gmbh	Genabschaltung (gene silencing) durch hybride sens-dna und antisens-rna konstrukte, gekoppelt an ein peptid zur erleichterten aufnahme in zellen
US20060118754A1 (en) *	2004-12-08	2006-06-08	Lapen Daniel C	Stabilizing a polyelectrolyte multilayer
US9809824B2 (en) *	2004-12-13	2017-11-07	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US7220549B2 (en)	2004-12-30	2007-05-22	Helicos Biosciences Corporation	Stabilizing a nucleic acid for nucleic acid sequencing
US20060172328A1 (en) *	2005-01-05	2006-08-03	Buzby Philip R	Methods and compositions for correcting misincorporation in a nucleic acid synthesis reaction
US7482120B2 (en) *	2005-01-28	2009-01-27	Helicos Biosciences Corporation	Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US7608433B2 (en)	2005-02-09	2009-10-27	Idexx Laboratories	Method of detection of classical swine fever
US20060263790A1 (en) *	2005-05-20	2006-11-23	Timothy Harris	Methods for improving fidelity in a nucleic acid synthesis reaction
JP2009501024A (ja) *	2005-07-12	2009-01-15	テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション	癌の診断及び治療における遺伝的及びエピジェネティックな変化
US7666593B2 (en)	2005-08-26	2010-02-23	Helicos Biosciences Corporation	Single molecule sequencing of captured nucleic acids
US20070202515A1 (en) *	2005-10-12	2007-08-30	Pathologica, Llc.	Promac signature application
US20070117102A1 (en) *	2005-11-22	2007-05-24	Buzby Philip R	Nucleotide analogs
US20070128610A1 (en) *	2005-12-02	2007-06-07	Buzby Philip R	Sample preparation method and apparatus for nucleic acid sequencing
US7579459B2 (en) *	2005-12-12	2009-08-25	Ngo Nam Q	Activator bound solid supports for nucleic acid synthesis via the phosphoramidite approach
WO2007070642A2 (en) *	2005-12-15	2007-06-21	Helicos Biosciences Corporation	Methods for increasing accuracy of nucleic acid sequencing
JP5342881B2 (ja)	2006-01-27	2013-11-13	アイシスファーマシューティカルズ，インコーポレーテッド	６−修飾された二環式核酸類似体
US7569686B1 (en)	2006-01-27	2009-08-04	Isis Pharmaceuticals, Inc.	Compounds and methods for synthesis of bicyclic nucleic acid analogs
US7397546B2 (en) *	2006-03-08	2008-07-08	Helicos Biosciences Corporation	Systems and methods for reducing detected intensity non-uniformity in a laser beam
US20080309926A1 (en) *	2006-03-08	2008-12-18	Aaron Weber	Systems and methods for reducing detected intensity non uniformity in a laser beam
CA2647260A1 (en) *	2006-03-24	2007-11-08	Archemix Corp.	Solid support reagents for synthesis
EP2023940B1 (en) *	2006-05-05	2011-06-22	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating expression of sglt2
AU2007249349B2 (en) *	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) *	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
WO2008027558A2 (en)	2006-08-31	2008-03-06	Codon Devices, Inc.	Iterative nucleic acid assembly using activation of vector-encoded traits
US7947447B2 (en)	2007-01-16	2011-05-24	Somalogic, Inc.	Method for generating aptamers with improved off-rates
EP2170917B1 (en)	2007-05-30	2012-06-27	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en)	2007-06-08	2015-11-04	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) *	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
US8404830B2 (en) *	2007-07-17	2013-03-26	Somalogic, Inc.	Method for generating aptamers with improved off-rates
US8680019B2 (en) *	2007-08-10	2014-03-25	Protelica, Inc.	Universal fibronectin Type III binding-domain libraries
US8470966B2 (en)	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) *	2007-08-10	2009-07-09	Protelix, Inc.	Universal fibronectin type III binding-domain libraries
WO2009023855A2 (en)	2007-08-15	2009-02-19	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
US20090180931A1 (en)	2007-09-17	2009-07-16	Sequenom, Inc.	Integrated robotic sample transfer device
US8546556B2 (en) *	2007-11-21	2013-10-01	Isis Pharmaceuticals, Inc	Carbocyclic alpha-L-bicyclic nucleic acid analogs
US9102711B2 (en) *	2007-12-31	2015-08-11	Xoma Technology Ltd.	Methods and materials for targeted mutagenesis
WO2009100320A2 (en) *	2008-02-07	2009-08-13	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexitol nucleic acid analogs
WO2009117589A1 (en)	2008-03-21	2009-09-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
DK2285819T3 (da) *	2008-04-04	2013-12-02	Isis Pharmaceuticals Inc	Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
WO2010005693A1 (en) *	2008-06-23	2010-01-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cyclized ngr peptide compounds, compositions, and methods of their use
US8691971B2 (en)	2008-09-23	2014-04-08	Scott G. Petersen	Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
WO2010036698A1 (en) *	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
US8604192B2 (en) *	2008-09-24	2013-12-10	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acids analogs
MX2011004097A (es)	2008-10-15	2011-07-28	Isis Pharmaceuticals Inc	Modulacion de la expresion del factor 11.
EP2358398A2 (en)	2008-10-24	2011-08-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
WO2010048549A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
WO2010065159A1 (en) *	2008-12-02	2010-06-10	Oregon Health & Science University	Inhibition of dna polymerases to augment chemotherapeutic and antimicrobial agents
RU2572826C2 (ru)	2008-12-02	2016-01-20	Чиралджен, Лтд.	Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
EP2389452A2 (en)	2009-01-21	2011-11-30	Vertex Pharmaceuticals Incorporated	Methods for amplifying hepatitis c virus nucleic acids
US8536320B2 (en)	2009-02-06	2013-09-17	Isis Pharmaceuticals, Inc.	Tetrahydropyran nucleic acid analogs
EP2669290A1 (en)	2009-03-02	2013-12-04	Alnylam Pharmaceuticals Inc.	Nucleic Acid Chemical Modifications
US7960526B2 (en) *	2009-03-30	2011-06-14	Berry And Associates, Inc.	Colorimetric-oxycarbonyl protecting groups for use in organic syntheses
CA2767253A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc.	Novel nucleic acid prodrugs and methods of use thereof
WO2011005861A1 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	Oligonucleotide end caps
US8927513B2 (en)	2009-07-07	2015-01-06	Alnylam Pharmaceuticals, Inc.	5′ phosphate mimics
EP2462153B1 (en)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
EP2494046B1 (en)	2009-10-30	2018-09-12	Novartis AG	Universal fibronectin type iii bottom-side binding domain libraries
US10207240B2 (en)	2009-11-03	2019-02-19	Gen9, Inc.	Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
EP2504449B1 (en)	2009-11-25	2016-03-23	Gen9, Inc.	Methods and apparatuses for chip-based dna error reduction
WO2011066185A1 (en)	2009-11-25	2011-06-03	Gen9, Inc.	Microfluidic devices and methods for gene synthesis
WO2011085075A2 (en)	2010-01-07	2011-07-14	Gen9, Inc.	Assembly of high fidelity polynucleotides
WO2011085102A1 (en)	2010-01-11	2011-07-14	Isis Pharmaceuticals, Inc.	Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011094580A2 (en)	2010-01-28	2011-08-04	Alnylam Pharmaceuticals, Inc.	Chelated copper for use in the preparation of conjugated oligonucleotides
US8716467B2 (en)	2010-03-03	2014-05-06	Gen9, Inc.	Methods and devices for nucleic acid synthesis
WO2011115818A1 (en)	2010-03-17	2011-09-22	Isis Pharmaceuticals, Inc.	5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011123621A2 (en)	2010-04-01	2011-10-06	Alnylam Pharmaceuticals Inc.	2' and 5' modified monomers and oligonucleotides
EP3345915B1 (en)	2010-04-12	2021-11-24	Somalogic, Inc.	5-position modified pyrimidines and their use
US10913767B2 (en)	2010-04-22	2021-02-09	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
WO2011133868A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	Conformationally restricted dinucleotide monomers and oligonucleotides
KR101869570B1 (ko)	2010-04-28	2018-06-20	아이오니스 파마수티컬즈, 인코포레이티드	변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
US9156873B2 (en)	2010-04-28	2015-10-13	Isis Pharmaceuticals, Inc.	Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en)	2010-04-28	2011-11-10	Isis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
US8957200B2 (en)	2010-06-07	2015-02-17	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2580228B1 (en)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011163121A1 (en)	2010-06-21	2011-12-29	Alnylam Pharmaceuticals, Inc.	Multifunctional copolymers for nucleic acid delivery
CN107903321A (zh)	2010-07-30	2018-04-13	诺华有限公司	纤连蛋白摇篮分子和其库
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
CN103502448B (zh)	2010-11-12	2017-03-29	Gen9股份有限公司	核酸合成的方法和设备
EP2637780B1 (en)	2010-11-12	2022-02-09	Gen9, Inc.	Protein arrays and methods of using and making the same
CA3077910A1 (en)	2010-11-17	2012-05-24	Ionis Pharmaceuticals, Inc.	Modulation of alpha synuclein expression
AR084358A1 (es)	2010-12-27	2013-05-08	Lilly Co Eli	Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
AU2011352800B2 (en)	2010-12-27	2015-09-03	Elanco Us Inc.	Bovine viral diarrhea virus type 1b vaccine compositions and methods
AU2011351946B2 (en)	2010-12-30	2017-05-18	Dow Agrosciences Llc	Nucleic acid molecules that target the vacuolar ATPase C subunit and confer resistance to coleopteran pests
RU2639549C2 (ru)	2010-12-30	2017-12-21	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Молекулы нуклеиновых кислот, которые придают устойчивость к насекомым-вредителям отряда жесткокрылых
UY33853A (es)	2010-12-30	2012-07-31	Dow Agrosciences Llc	?moléculas de ácido nucleico que se dirigen a la subunidad h de la atpasa vacuolar y confieren resistencia a plagas de coleópteros?.
RU2013135491A (ru)	2010-12-30	2015-02-10	Дау Агросайенсиз Ллс	Молекулы нуклеиновых кислот, которые нацелены на малый gtp-связывающий белок rho1 и сообщают устойчивость к вредителям отряда жесткокрылых
WO2012170347A1 (en)	2011-06-09	2012-12-13	Isis Pharmaceuticals, Inc.	Bicyclic nucleosides and oligomeric compounds prepared therefrom
AU2012284265B2 (en)	2011-07-19	2017-08-17	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
LT2944693T (lt)	2011-08-26	2019-08-26	Gen9, Inc.	Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
HK1200484A1 (zh)	2011-09-14	2015-08-07	Translate Bio Ma, Inc.	多聚寡核苷酸化合物
JP2015502365A (ja)	2011-12-12	2015-01-22	オンコイミューニン，インコーポレイティド	オリゴヌクレオチドのイン−ビボ送達
US9150853B2 (en)	2012-03-21	2015-10-06	Gen9, Inc.	Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
WO2013154799A1 (en)	2012-04-09	2013-10-17	Isis Pharmaceuticals, Inc.	Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (en)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Tricyclic nucleic acid analogs
CN111876409A (zh)	2012-04-24	2020-11-03	Gen9股份有限公司	在体外克隆中分选核酸和多重制备物的方法
EP2844775B1 (en)	2012-05-02	2018-07-18	Ibis Biosciences, Inc.	Dna sequencing
WO2013166303A1 (en)	2012-05-02	2013-11-07	Ibis Biosciences, Inc.	Dna sequencing
CA2873766A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics Inc.	Compositions and methods for modulating atp2a2 expression
CA2873769A1 (en)	2012-05-16	2013-11-21	Rana Therapeutics Inc.	Compositions and methods for modulating hemoglobin gene family expression
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
BR112014028634A2 (pt)	2012-05-16	2017-06-27	Rana Therapeutics Inc	composições e métodos para modulação da expressão de utrn
JP2015523854A (ja)	2012-05-16	2015-08-20	ラナセラピューティクスインコーポレイテッド	Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
AU2013262709A1 (en)	2012-05-16	2015-01-22	Rana Therapeutics, Inc.	Compositions and methods for modulating MECP2 expression
US10458915B2 (en)	2012-05-18	2019-10-29	Pacific Biosciences Of California, Inc.	Heteroarylcyanine dyes
AU2013280661A1 (en)	2012-06-25	2015-01-22	Gen9, Inc.	Methods for nucleic acid assembly and high throughput sequencing
SG11201500239VA (en)	2012-07-13	2015-03-30	Wave Life Sciences Japan	Asymmetric auxiliary group
CN104684923B (zh)	2012-07-13	2018-09-28	株式会社新日本科学	手性核酸佐剂
JP6453212B2 (ja)	2012-07-13	2019-01-16	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	キラル制御
EP2885312B1 (en)	2012-08-15	2025-09-03	Ionis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified capping protocols
US9950001B2 (en)	2012-08-20	2018-04-24	The Regents Of The University Of California	Polynucleotides having bioreversible groups
EP2895200B1 (en)	2012-09-14	2019-11-06	Translate Bio MA, Inc.	Multimeric oligonucleotide compounds
US9029335B2 (en)	2012-10-16	2015-05-12	Isis Pharmaceuticals, Inc.	Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US20160046997A1 (en)	2012-10-18	2016-02-18	Oslo Universitetssykehus Hf	Biomarkers for cervical cancer
WO2014063051A2 (en)	2012-10-18	2014-04-24	Idexx Laboratories, Inc.	Nucleic acid amplification controls and kits and methods of use thereof
WO2014120861A2 (en)	2013-01-31	2014-08-07	Isis Pharmaceuticals, Inc.	Method of preparing oligomeric compounds using modified coupling protocols
US10280417B2 (en)	2013-03-13	2019-05-07	Gen 9, Inc.	Compositions, methods and apparatus for oligonucleotides synthesis
DK2991656T3 (da)	2013-05-01	2020-03-23	Ionis Pharmaceuticals Inc	Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
JP2016531570A (ja)	2013-08-16	2016-10-13	ラナセラピューティクスインコーポレイテッド	ユークロマチン領域を標的とするオリゴヌクレオチド
CA2921457A1 (en) *	2013-08-16	2015-02-19	Rana Therapeutics, Inc.	Heterochromatin forming non-coding rnas
US11162096B2 (en)	2013-10-14	2021-11-02	Ionis Pharmaceuticals, Inc	Methods for modulating expression of C9ORF72 antisense transcript
WO2015061246A1 (en)	2013-10-21	2015-04-30	Isis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
BR112016010165A2 (pt)	2013-11-21	2017-12-05	Somalogic Inc	composições de nucleotídeos modificados de citidina-5-carboxamida e métodos relacionados às mesmas
RU2016129435A (ru)	2013-12-20	2018-01-25	ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи	Молекулы нуклеиновой кислоты phkп ii-140, которые придают устойчивость к жестококрылым насекомым-вредителям
BR102014031844A2 (pt)	2013-12-20	2015-10-06	Dow Agrosciences Llc	ras oposto (rop) e moléculas de ácido nucleico relacionadas que conferem resistência a pragas de coleópteros e hemípteros
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
ES2917473T3 (es)	2014-01-16	2022-07-08	Wave Life Sciences Ltd	Diseño quiral
EP3119789B1 (en)	2014-03-17	2020-04-22	Ionis Pharmaceuticals, Inc.	Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143245A1 (en)	2014-03-19	2015-09-24	Isis Pharmaceuticals, Inc.	Methods for modulating ataxin 2 expression
CN106103717A (zh)	2014-03-19	2016-11-09	Ionis制药公司	用于调节共济失调蛋白2表达的组合物
RS60707B1 (sr)	2014-04-01	2020-09-30	Biogen Ma Inc	Kompozicije za modulaciju ekspresije sod-1
WO2015164693A1 (en)	2014-04-24	2015-10-29	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising alpha-beta-constrained nucleic acid
DK3137476T3 (da)	2014-04-28	2019-11-18	Ionis Pharmaceuticals Inc	Linker-modificerede oligomerforbindelser
SG11201608502TA (en)	2014-05-01	2016-11-29	Ionis Pharmaceuticals Inc	Compositions and methods for modulating complement factor b expression
US10098959B2 (en)	2014-05-01	2018-10-16	Ionis Pharmaceuticals, Inc.	Method for synthesis of reactive conjugate clusters
AU2015255995B2 (en)	2014-05-07	2018-05-10	Dow Agrosciences Llc	Dre4 nucleic acid molecules that confer resistance to coleopteran pests
US10093967B2 (en)	2014-08-12	2018-10-09	The Regents Of The University Of Michigan	Detection of nucleic acids
BR112017004056A2 (pt)	2014-09-12	2017-12-05	Biogen Ma Inc	composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
EP3037432B1 (en)	2014-12-22	2020-06-17	Dow AgroSciences LLC	Nucampholin nucleic acid molecules to control coleopteran insect pests
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
US10538763B2 (en)	2015-01-16	2020-01-21	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulation of DUX4
WO2016130943A1 (en)	2015-02-13	2016-08-18	Rana Therapeutics, Inc.	Hybrid oligonucleotides and uses thereof
WO2016137923A1 (en)	2015-02-23	2016-09-01	Ionis Pharmaceuticals, Inc.	Method for solution phase detritylation of oligomeric compounds
US11129844B2 (en)	2015-03-03	2021-09-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating MECP2 expression
EP3067424A1 (en)	2015-03-13	2016-09-14	Dow AgroSciences LLC	Rna polymerase i1 nucleic acid molecules to control insect pests
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
BR102016012010A2 (pt)	2015-05-29	2020-03-24	Dow Agrosciences Llc	Molécula de ácido nucleico, de ácido ribonucleico (rna) e de ácido ribonucleico de filamento duplo (dsrna), usos de célula, planta e semente, produto primário, bem como métodos para controlar uma população de pragas coleópteras e/ou hemípteras, para melhorar o rendimento de uma cultura, e para produzir uma célula vegetal transgênica e uma planta transgênica
CN108135921B (zh)	2015-07-22	2023-10-17	波涛生命科学有限公司	寡核苷酸组合物及其方法
US10533175B2 (en)	2015-09-25	2020-01-14	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulating Ataxin 3 expression
US11058709B1 (en)	2015-12-04	2021-07-13	Ionis Pharmaceuticals, Inc.	Methods of treating breast cancer
US20190002887A1 (en)	2015-12-31	2019-01-03	Ionis Pharmaceuticals, Inc.	Methods for reducing ataxin-2 expression
CA3006599A1 (en)	2016-01-05	2017-07-13	Ionis Pharmaceuticals, Inc.	Methods for reducing lrrk2 expression
WO2017161168A1 (en)	2016-03-16	2017-09-21	Ionis Pharmaceuticals, Inc.	Modulation of dyrk1b expression
AU2017234678A1 (en)	2016-03-16	2018-08-16	Ionis Pharmaceuticals, Inc.	Methods of modulating KEAP1
EP3471781A4 (en)	2016-06-17	2020-05-06	Ionis Pharmaceuticals, Inc.	MODULATION OF GYS1 EXPRESSION
JP2019532027A (ja)	2016-08-17	2019-11-07	ソルスティスバイオロジクス，リミティッド	ポリヌクレオチド構築物
WO2018055577A1 (en)	2016-09-23	2018-03-29	Synthena Ag	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
EP3522898A4 (en)	2016-10-06	2020-05-27	Ionis Pharmaceuticals, Inc.	METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS
JOP20190104A1 (ar)	2016-11-10	2019-05-07	Ionis Pharmaceuticals Inc	مركبات وطرق لتقليل التعبير عن atxn3
WO2018089237A1 (en)	2016-11-10	2018-05-17	Dow Agrosciences Llc	Cytochrome b (cytb) nucleic acid molecules that control pathogens
MA46905A (fr) *	2016-11-23	2019-10-02	Wave Life Sciences Ltd	Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
WO2018102745A1 (en)	2016-12-02	2018-06-07	Cold Spring Harbor Laboratory	Modulation of lnc05 expression
EP3342780A1 (en)	2016-12-30	2018-07-04	Dow AgroSciences LLC	Pre-mrna processing factor 8 (prp8) nucleic acid molecules to control insect pests
AU2018231211A1 (en)	2017-03-08	2019-10-03	The Regents Of The University Of Michigan	Analyte detection
US11180756B2 (en)	2017-03-09	2021-11-23	Ionis Pharmaceuticals	Morpholino modified oligomeric compounds
WO2019006455A1 (en)	2017-06-30	2019-01-03	Solstice Biologics, Ltd.	AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US11197884B2 (en)	2017-08-18	2021-12-14	Ionis Pharmaceuticals, Inc.	Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en)	2017-09-08	2019-12-31	Ionis Pharmaceuticals, Inc.	Modulators of SMAD7 expression
TWI809004B (zh)	2017-11-09	2023-07-21	美商Ionis製藥公司	用於降低snca表現之化合物及方法
US11459564B2 (en)	2017-12-21	2022-10-04	Ionis Pharmaceuticals, Inc.	Modulation of frataxin expression
BR112020014425A2 (pt)	2018-01-15	2020-12-29	Ionis Pharmaceuticals, Inc.	Moduladores de expressão de dnm2
TWI840345B (zh)	2018-03-02	2024-05-01	美商Ionis製藥公司	Irf4表現之調節劑
EP3759127A4 (en)	2018-03-02	2022-03-30	Ionis Pharmaceuticals, Inc.	COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
US11661601B2 (en)	2018-03-22	2023-05-30	Ionis Pharmaceuticals, Inc.	Methods for modulating FMR1 expression
CA3094020A1 (en)	2018-04-11	2019-10-17	Ionis Pharmaceuticals, Inc.	Modulators of ezh2 expression
US11613554B2 (en)	2018-04-13	2023-03-28	Bristol-Myers Squibb Company	Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
SG11202010215TA (en)	2018-05-09	2020-11-27	Ionis Pharmaceuticals Inc	Compounds and methods for reducing atxn3 expression
JP7438135B2 (ja)	2018-05-09	2024-02-26	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｆｘｉの発現を低下させるための化合物及び方法
CA3103429A1 (en)	2018-06-14	2019-12-19	Don W. Cleveland	Compounds and methods for increasing stmn2 expression
TWI833770B (zh)	2018-06-27	2024-03-01	美商Ionis製藥公司	用於減少 lrrk2 表現之化合物及方法
EP3823725A4 (en)	2018-07-17	2023-05-10	Aronora, Inc.	METHODS FOR SAFELY REDUCING THROMBOPOIETIN
BR112021000308A2 (pt)	2018-07-25	2021-04-13	Ionis Pharmaceuticals, Inc.	Compostos e métodos para redução da expressão de atxn2
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
BR112021008967A2 (pt)	2018-11-15	2021-08-17	Ionis Pharmaceuticals, Inc.	moduladores da expressão de irf5
SG11202103794QA (en)	2018-11-21	2021-05-28	Ionis Pharmaceuticals Inc	Compounds and methods for reducing prion expression
SG11202107399WA (en)	2019-01-31	2021-08-30	Ionis Pharmaceuticals Inc	Modulators of yap1 expression
TW202540426A (zh)	2019-02-27	2025-10-16	美商Ionis製藥公司	Malat1表現之調節劑
FI3947684T3 (fi)	2019-03-29	2025-05-27	Ionis Pharmaceuticals Inc	Yhdisteitä ja menetelmiä ube3a-ats:n moduloimiseksi
EP3956450B1 (en)	2019-07-26	2025-08-13	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating gfap
EP4013767A4 (en)	2019-08-15	2023-10-25	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds and uses thereof
CN111039977B (zh) *	2019-12-31	2022-11-08	广州同隽医药科技有限公司	一种亚磷酰化试剂及其在寡核苷酸合成中的应用
CR20220485A (es)	2020-02-28	2022-11-10	Ionis Pharmaceuticals Inc	Compuestos y métodos para modular smn2
MX2022013707A (es)	2020-05-01	2022-12-07	Ionis Pharmaceuticals Inc	Compuestos y metodos para modular atxn1.
BR112022024206A2 (pt)	2020-06-29	2023-01-03	Ionis Pharmaceuticals Inc	Compostos e métodos para modular plp1
AU2021315992A1 (en)	2020-07-28	2023-02-09	Ionis Pharmaceuticals, Inc.	Compounds and methods for reducing app expression
IL300258A (en)	2020-08-07	2023-03-01	Ionis Pharmaceuticals Inc	Compounds and methods for modulating SCN2A
EP4136092B1 (en)	2020-11-18	2024-07-31	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating angiotensinogen expression
JP2023554346A (ja)	2020-12-18	2023-12-27	アイオーニスファーマシューティカルズ，インコーポレーテッド	第ｘｉｉ因子を調節するための化合物及び方法
WO2022256303A1 (en)	2021-05-31	2022-12-08	Genscript Usa Inc.	Electrografted films for dna synthesis
KR20240023602A (ko)	2021-06-18	2024-02-22	아이오니스 파마수티컬즈, 인코포레이티드	Ifnar1 발현을 감소시키기 위한 화합물 및 방법
EP4569112A1 (en)	2022-08-12	2025-06-18	Remix Therapeutics Inc.	Methods and compositions for modulating splicing at alternative splice sites
JP2025532127A (ja)	2022-09-23	2025-09-29	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｍｅｃｐ２発現を低減する化合物及び方法
US12168674B1 (en)	2023-12-08	2024-12-17	Oligo Foundry, Inc.	Reagents and methods for the highly-efficient synthesis and purification of biopolymers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310662A (en) *	1979-12-26	1982-01-12	Genentech, Inc.	Nucleosidic phosphorylating agent and methods
DE3177215D1 (de)	1980-02-29	1990-10-25	University Patents Inc	Verfahren zur herstellung von modifizierten anorganischen polymeren.
US4500707A (en) *	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US4458066A (en) *	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
IL62834A0 (en) *	1980-05-14	1981-07-31	Ens Bio Logicals Inc	Polynucleotide synthesis
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
NL8102323A (nl) *	1981-05-12	1982-12-01	Unilever Nv	Fosforzuurderivaten, werkwijze ter bereiding daarvan, alsmede werkwijze voor het fosforyleren van organische hydroxylverbindingen en fosfortriesterintermediairen voor gebruik in de synthese van desoxy- en ribo-nucleinezuren (dna en rna).
US4419509A (en) *	1981-08-24	1983-12-06	Eli Lilly And Company	Process for de-cyanoethylating blocked nucleotides
EP0090789A1 (en) *	1982-03-26	1983-10-05	Monsanto Company	Chemical DNA synthesis
US4476301A (en) *	1982-04-29	1984-10-09	Centre National De La Recherche Scientifique	Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4605735A (en) *	1983-02-14	1986-08-12	Wakunaga Seiyaku Kabushiki Kaisha	Oligonucleotide derivatives
NL8302353A (nl) *	1983-07-01	1985-02-01	Stichting Katholieke Univ	Fosforyleringsmiddel; werkwijze voor het bereiden daarvan; werkwijze voor het fosforyleren van een organische hydroxyl- of amineverbinding.
US4591614A (en) *	1983-10-07	1986-05-27	The Johns Hopkins University	Preparation of oligodeoxyribonucleoside alkyl or arylphosphonates

1983
- 1983-08-18 DE DE19833329892 patent/DE3329892A1/de not_active Withdrawn
1984
- 1984-08-10 DE DE8484903173T patent/DE3474964D1/de not_active Expired
- 1984-08-10 AT AT84903173T patent/ATE38386T1/de not_active IP Right Cessation
- 1984-08-10 US US06/752,178 patent/US4725677A/en not_active Ceased
- 1984-08-10 JP JP59503282A patent/JPS60502102A/ja active Granted
- 1984-08-10 AU AU33137/84A patent/AU3313784A/en not_active Abandoned
- 1984-08-10 EP EP84903173A patent/EP0152459B1/de not_active Expired
- 1984-08-10 WO PCT/EP1984/000244 patent/WO1985000816A1/de not_active Ceased
- 1984-08-17 CA CA000461270A patent/CA1234060A/en not_active Expired
- 1984-08-17 IT IT09482/84A patent/IT1198910B/it active
1989
- 1989-01-31 JP JP1023614A patent/JPH01301691A/ja active Granted

Also Published As

Publication number	Publication date
AU3313784A (en)	1985-03-12
JPH01301691A (ja)	1989-12-05
IT8409482A0 (it)	1984-08-17
CA1234060A (en)	1988-03-15
EP0152459B1 (de)	1988-11-02
DE3329892A1 (de)	1985-03-07
IT1198910B (it)	1988-12-21
WO1985000816A1 (fr)	1985-02-28
EP0152459A1 (de)	1985-08-28
JPS6250479B2 (2)	1987-10-24
US4725677A (en)	1988-02-16
JPS60502102A (ja)	1985-12-05
ATE38386T1 (de)	1988-11-15
DE3474964D1 (en)	1988-12-08

Legal Events

Date	Code	Title	Description
2004-08-10	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
JPH0411555B2 (2)	1992-02-28
USRE34069E (en)	1992-09-15	Process for the preparation of oligonucleotides
KR102531388B1 (ko)	2023-05-11	알콕시 페닐 유도체, 뉴클레오시드 보호체 및 뉴클레오티드 보호체, 올리고뉴클레오티드 제조 방법, 및 치환기 제거 방법
US5218088A (en)	1993-06-08	Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates
JP7484951B2 (ja)	2024-05-16	オリゴヌクレオチドの製造方法
WO2005085272A1 (ja)	2005-09-15	ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
EA003091B1 (ru)	2002-12-26	Синтез олигонуклеотидов в жидкой фазе
EP1317466B1 (en)	2005-02-23	Synthons for oligonucleotide synthesis
EP0611075B1 (en)	1996-12-18	Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
US20070004911A1 (en)	2007-01-04	Silylated oligonucleotide compounds
JP2006248949A (ja)	2006-09-21	ヌクレオシド誘導体、ヌクレオチド誘導体及びそれらの製造方法
CN100484949C (zh)	2009-05-06	用于rna寡核苷酸合成中的核苷亚磷酰胺及其合成方法
JP7075681B2 (ja)	2022-05-26	立体制御オリゴヌクレオチド合成用光学活性セグメントおよびその製造方法、ならびにそれを用いた立体制御オリゴヌクレオチドの合成方法
JPH0291088A (ja)	1990-03-30	ホスファイトおよびヌクレオシド‐３’‐ホスファイト誘導体およびこれを用いるオリゴヌクレオチドの合成法
JP7296636B2 (ja)	2023-06-23	アルコキシフェニル誘導体、ヌクレオシド保護体およびヌクレオチド保護体、オリゴヌクレオチド製造方法、ならびに、置換基除去方法
JP3669208B2 (ja)	2005-07-06	ヌクレオチドブロックの製造方法、ヌクレオチドおよびヌクレオチドブロック
JPWO1999021872A1 (ja)	2001-04-10	ヌクレオチド化合物及びオリゴヌクレオチドの合成法
JPH10259192A (ja)	1998-09-29	ホスホロチオエートジエステル化合物の製造法
JPH04112894A (ja)	1992-04-14	ホスフィン化合物及びこれを用いるオリゴヌクレオチドの合成方法
HK1000191B (en)	1998-01-27	Modified oligodeoxyribonucleotides, their preparation and their therapeutic use
JPS6363695A (ja)	1988-03-22	ヌクレオシドホスホロチオイツトを用いたオリゴヌクレオチドの固相合成法